BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 9768629)

  • 1. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
    Moorman AC; Von Bargen JC; Palella FJ; Holmberg SD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):182-8. PubMed ID: 9768629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
    Simonds RJ; Hughes WT; Feinberg J; Navin TR
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S44-8. PubMed ID: 8547511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
    Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
    Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
    Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
    Chan C; Montaner J; Lefebvre EA; Morey G; Dohn M; McIvor RA; Scott J; Marina R; Caldwell P
    J Infect Dis; 1999 Aug; 180(2):369-76. PubMed ID: 10395851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.
    May T; Beuscart C; Reynes J; Marchou B; Leclercq P; Borsa Lebas F; Saba J; Micoud M; Mouton Y; Canton P
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):457-62. PubMed ID: 8158539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incidence of bacterial pneumonia in HIV-positive patients treated with preventive co-trimoxazole or pentamidine].
    Koch A; Kothe H; Braun J; Kämmerer R; Friedrich HJ; Dalhoff K
    Pneumologie; 1998 Nov; 52(11):614-21. PubMed ID: 9885511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
    Korraa H; Saadeh C
    South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing PCP therapy.
    Torres G; Cadman J
    GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
    Sackoff J; McFarland J; Su S; Bryan E
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):387-92. PubMed ID: 9833748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
    Hughes WT
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Bucher HC; Griffith L; Guyatt GH; Opravil M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.
    Nielsen TL; Jensen BN; Nelsing S; Mathiesen LR; Skinhøj P; Nielsen JO
    Scand J Infect Dis; 1995; 27(3):217-20. PubMed ID: 8539544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.